CanREValue Interim Data Report Open for Feedback

The CanREValue Collaboration is pleased to open the feedback consultation period for our first Data Working Group Interim Report: Mapping Canadian Provincial Data Assets to Conduct Real-World Studies on Cancer Drugs. View the Interim Data Working Group Report here View the Report Appendix here Feedback Form We welcome any stakeholder (more…)

Engagement Webinar Recording & Slides Now Available

We have now uploaded a copy of the slides and a full recording of our Stakeholder Engagement Webinar which was held on Wednesday November 6th 2019. View a copy of the slide deck here Listen to & watch the recorded webinar here Please feel free to share these links with (more…)

Article: Is There Evidence in Real-World Evidence?

“Evidence from real-world practice and utilization—outside of clinical trials—is seen to tailor healthcare decision-making more closely to the characteristics of individual patients, and thus as a step towards making healthcare more personalized and effective.” A new overview on the potential uses and benefits of RWE has been published by, authored (more…)

Welcome to the CanREValue Website

CanREValue is happy to announce our initial website is now live! Still under construction, we expect the Working Group and Resources sections to be populated in early 2019, and we will also upload copies of presentations & abstracts on the Knowledge Translation page. Should you have any questions about the (more…)

FDA’s RWE Framework

Earlier in December the FDA released a new framework outlining how they will use Real World Evidence (RWE) and Real World Data (RWD) in decision making for new drugs and biologics.  Under the new framework, the FDA will use the following three criteria to evaluate RWE/RWD: 1. Whether the RWD are fit (more…)